BMS and Apexigen to assess Opdivo + APX005M combination for NSCLC

Bristol-Myers Squibb (BMS) has entered a clinical collaboration with biopharmaceutical firm Apexigen to assess the combination of Opdivo (nivolumab) with APX005M for the treatment of advanced solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsDecrease in the rates of perioperative outcomes parallels improvements in patient selection and perioperative management of early-stage NSCLC resection patients. Predictors of pulmonary complication could be used to improve selection criteria for surgery and to reduce the incidence of pulmonary complication in these patients.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Streptomyces-derived natural products have been become a major focus of anti-tumor drug discovery studies. Neoantimycin F (NAT-F), was isolated from Streptomyces conglobatus by our group. Here, we examined the anti-cancer activities and its underlying molecular mechanisms implicated in NAT-F–induced apoptosis of non–small cell lung cancer (NSCLC) cells. Our results showed that NAT-F exerted excellent growth-inhibitory activity against PC9 and H1299 cells in a concentration-dependent manner. NAT-F–induced cell cycle arrest at S and G0/G1 phase in PC9 and H1299 cells, respectively. Further investigation rev...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Condition:   Non-Small Cell Lung Cancer Intervention:   Drug: Pembrolizumab Sponsors:   Canadian Cancer Trials Group;   Cancer Research Institute, New York City;   Personal Genome Diagnostics (PGDx);   Mark Foundation Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Patient Outcome Assessment;   Morbidity;   Mortality Intervention:   Procedure: Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy Sponsor:   AHEPA University Hospital Completed
Source: - Category: Research Source Type: clinical trials
Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Unresectable Lung Non-Small Cell Carcinoma Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Biological: Durvalumab;   Drug: Etoposide;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Pemetre...
Source: - Category: Research Source Type: clinical trials
In conclusion, lncRNA SLNCR1 may regulate cancer cell migration, invasion and stemness in NSCLC through interactions with sPLA2. PMID: 31524254 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
ConclusionsBMP signaling inhibition in LCLC-103H cells leads to reduced growth and proliferation, hindered migration and accelerated cell death. The findings contribute to the pool of evidence on BMP signaling in lung cancer with a possibility of introducing BMP signaling inhibition as a novel therapeutic approach for the disease.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAnti-programmed cell death receptor (PD)-1 antibody treatment results in better prognosis than standard chemotherapy in patients with non-small cell lung cancer (NSCLC), especially those with high PD-ligand 1 (PD-L1) expression. However, several studies have reported a lack of antitumor effect of PD-1 antibody, even in patients with high PD-L1 expression. Therefore, reliable predictors of treatment response are urgently needed. The albumin –globulin ratio (AGR) is associated with prognosis in several cancers. We aimed to determine whether AGR is a predictive biomarker of anti-PD-1 antibody response ...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThese results indicate that the SNP538(G  >  A) in theABCC11 gene is a potential determinant for S-1 treatment.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
-Vila Rafael Rosell BRAF V600 mutations have been found in 1–2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50–80% of BRAF mutations in lung cancer are non-V600, and can be class II, with intermediate to high kinase activity and RAS independence, or class III, with impaired kinase activity, upstream signaling dependence, and consequently, sensitivity to receptor tyrosine kinase (RTK) inhibitors. Plasma cell-free DNA (cfDNA) of 185 newly diagnosed...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Non-Small Cell Lung Cancer | Pharmaceuticals